ALKERMES | ALKS - Net Income


ALKERMES reported $501K in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
AbbVie USD 3.61B 2.92B Jun/2026
Acadia Pharmaceuticals USD 31.5M 27.86M Jun/2026
ALKERMES USD 501K 66.98M Jun/2026
Amgen USD 2.38B 556M Jun/2026
Biogen USD 97.5M 222M Jun/2026
BioMarin Pharmaceutical USD 44.76M 60.76M Jun/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Coherus Biosciences USD -37.64M 2.11M Dec/2025
Eli Lilly USD 7.1B 301M Jun/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
J&J USD 5.53B 299M Jun/2026
Malin Corporation EUR -1.1M 2.2M Dec/2023
Merck USD -1.34B 2.9B Jun/2026
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Nektar Therapeutics USD -44.9M 8.82M Mar/2026
Neurocrine Biosciences USD 144.4M 53.5M Jun/2026
Otsuka Holdings JPY 117.26B 18.92B Jun/2026
Ovoca Bio EUR 4.42M 5.19M Dec/2025
Pfizer USD -248M 2.94B Jun/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Vertex Pharmaceuticals USD 1.1B 68.4M Jun/2026